Devices, biologics, and outcomes data — engineered as one connected ecosystem with recurring, ownable economics. Now raising on Wefunder.
Investing in early-stage companies is highly speculative and involves risk, including the loss of your entire investment. This is not an offer to sell securities; any investment is made only through the offering materials on Wefunder.
Medical aesthetics is one of the fastest-growing, largely cash-pay segments in healthcare, yet it remains highly fragmented and device-led. Regenera is built around the part most operators leave on the table: recurring revenue.
The U.S. medical-aesthetics and regenerative-wellness markets are large, growing double digits annually, and overwhelmingly cash-pay — insulated from reimbursement pressure.
The model proven by Intuitive Surgical and InMode: place the platform, then earn on the recurring, owned consumables that every treatment requires.
Regenera owns the device layer, the exclusive consumable and biologic layer, and the outcomes-data layer — so value compounds with every treatment performed.
Each layer reinforces the others. The device creates the channel, the biologic is the recurring payload, and the data proves the outcome — a loop competitors can't easily copy.
A patent-pending plasma console platform that runs the treatments and connects every clinic — the rails the rest of the ecosystem rides on.
A proprietary biologics line developed under Chief Scientific Officer Dr. Jonathan R.T. Lakey — a cosmetic line today, with a disciplined, regulated pipeline behind it.
Diametrics.ai (in development) captures results across the network — turning treatments into outcomes data that strengthens providers, payers, and the brand.
Regenera Holdings brings together four focused subsidiaries — each its own business, sharing one platform and one ecosystem.
The Florida-based parent uniting the device, biologics, licensing, and data companies under a single regenerative-aesthetics platform.
The connected plasma console platform and its intellectual property. The PlasmaPen acquisition is a structured transaction currently in progress.
Proprietary regenerative biologics led by CSO Dr. Jonathan R.T. Lakey — a cosmetic line today and a regulated medical pipeline in development.
The outcomes and analytics layer — Results-as-a-Service — capturing measurable data across the provider network. In development.
The Authorized Provider License Program that places the platform into multi-location clinics and groups under a structured license.
Regenera Holdings is opening this round to the public through Wefunder, so the people who believe in regenerative aesthetics can own a part of the platform building it.
This page is informational only and is not an offer to sell or a solicitation to buy securities. Any investment is made solely through the official offering materials, including the Form C, on Wefunder. Investing involves risk, including the loss of your entire investment — invest only what you can afford to lose.